WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday,...
Category: News
Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on...
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results after the close of the U.S. financial markets on Thursday, August 6, 2020. Nabriva’s...
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 2020 Wedbush PacGrow Healthcare Virtual...
Everest Medicines Announces Positive Results from In Vitro Study of Taniborbactam (VNRX-5133) in Combination with Cefepime
Shanghai, China, April 9, 2020 — Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced the results from an in vitro study of taniborbactam (VNRX-5133) combined with cefepime. The study assessed the in vitro activity of the novel beta-lactamase...
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
July 23, 2020 at 7:00 AM EDT -In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties of Lefamulin DUBLIN, Ireland, July 23, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development...
Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row
Malvern, PA, June 30, 2020 – Venatorx Pharmaceuticals today announced that it was named one of the “2020 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal. The Philadelphia Business Journal, in partnership with Quantum Workplace, honors companies based on a scoring benchmark, which reflects employee...
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4...
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
–XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, July 28, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV) announced today that the European Commission...
Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen
Venatorx Pharmaceuticals announced today that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID)